One is Regadenoson, an A2AR agonistapproved for use in myocardial perfusion imaging (157, 158), andIstradefylline, an A2AR antagonist approved for use in combination with othertherapies for the management of Parkinson’s disease (159). Here, ADORA2A is linked to Parkinson disease.